|
Synonyms: CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700
reslizumab is an approved drug (EMA & FDA (2016))
Compound class:
Antibody
Comment: Reslizumab is a monoclonal antibody with antiinflammatory action. It is designed to treat eosinophil-driven inflammatory conditions of the airways, skin and gastrointestinal tract [1,4].
View more information in the IUPHAR Pharmacology Education Project: reslizumab |
| References |
|
1. Bodmer MW, Athwal DS, Emtage JS. (1999)
Interleukin-5 specific recombinant antibodies. Patent number: US5998586. Assignee: Celltech Therapeutics, Limited. Priority date: 17/06/1994. Publication date: 07/12/1999. |
|
2. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. (2016)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest, 150 (4): 799-810. [PMID:27018175] |
|
3. Shen HH, Ochkur SI, McGarry MP, Crosby JR, Hines EM, Borchers MT, Wang H, Biechelle TL, O'Neill KR, Ansay TL et al.. (2003)
A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol, 170 (6): 3296-305. [PMID:12626589] |
|
4. Walsh GM. (2009)
Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther, 11 (3): 329-36. [PMID:19479666] |
